Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?
Alexandre E MalekPublished in: British journal of cancer (2021)
The use of granulocyte colony-stimulating factor (G-CSF) in patients with haematological malignancies is associated with less febrile neutropenia episodes. But in the presence of COVID-19 infection, the administration of G-CSF is challenging as it may trigger a robust inflammatory reaction resulting in cytokine storm, respiratory failure and severe outcomes.
Keyphrases
- respiratory failure
- coronavirus disease
- extracorporeal membrane oxygenation
- cell therapy
- sars cov
- stem cell transplantation
- mechanical ventilation
- bone marrow
- single cell
- cerebrospinal fluid
- chemotherapy induced
- early onset
- type diabetes
- peripheral blood
- mesenchymal stem cells
- metabolic syndrome
- intensive care unit
- hematopoietic stem cell
- recombinant human